Katherine joins us after nearly a decade in the pharmaceutical and medical device industry with vast experience in Phase I to IV studies. She has over three years of experience in ophthalmology with a focus in presbyopia at Allergan and AbbVie. She played a key role in patient recruitment and clinical site establishment as well as maintaining relationships with study site investigators and staff to optimize performance on clinical trial activities. Most recently she participated in the efforts to gain FDA approval for VUITYTM, the world’s first approved presbyopia correcting eye drop. Outside of ophthalmology, she has worked on multiple in-house and field studies at Candel Therapeutics in oncology, Beckman Coulter in infectious diseases and fertility, and at Dexcom in diabetes. In addition, she contributed to the 510K FDA submission which received approval for the AMH Immunoassay.
Katherine is passionate about clinical research and drug development and hopes to contribute to helping to bring better medicines to people who need it. Katherine holds a BS in Biology with an emphasis in medical sciences and physiology from California State University San Marcos.